ArticleClinical, cosmetic and investigational dermatology2026
Osimertinib, a Trigger of Subacute Cutaneous Lupus Erythematosus: Three-Patient Case Series and Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC). While acneiform rash, pruritus, xerosis and paronychia are well-recognized cutaneous adverse events of EGFR-TKIs, drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an emerging and under-recognized complication that may be misdiagnosed as eczema, psoriasis or drug allergic reaction, potentially leading to inappropriate management and permanent discontinuation of life-prolonging targeted therapy. Case Presentations: We report three female patients (aged 55-80 years) with EGFR-mutant NSCLC who developed DI-SCLE during osimertinib therapy, presenting with characteristic annular and polycyclic erythematous plaques in a photodistributed location 3-17 months after treatment initiation. Histopathological examination revealed irregularly thin epidermis with dyskeratotic keratinocytes, interface lymphocytic infiltrate and vacuolar degeneration of the basal layer in all cases corresponding to subacute cutaneous lupus erythematosus. Direct immunofluorescence demonstrated immunoglobulin and complement deposition along the dermoepidermal junction in two of three patients (positive lupus band test). All patients were managed with systemic corticosteroids and antimalarials (hydroxychloroquine or chloroquine) additionally used in two patients. This approach enabled continuation or resumption of osimertinib. Conclusion: These three cases establish osimertinib-induced SCLE as a recognizable clinical entity. Early dermatologic referral with skin biopsy and direct immunofluorescence is essential for accurate diagnosis, enabling appropriate immunosuppressive management while preserving access to life-prolonging targeted therapy. Early recognition therefore allows appropriate dermatologic management while maintaining effective oncologic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.